HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

By BioPharma Dive · Jun 9, 2026 · via BioPharma Dive
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFiercePharma ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 12, 2026
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
The WeekFierceBiotech ↗
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, set…
Jun 12, 2026
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
The WeekBriefing
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson reported pivotal trial success for Imaavy in warm autoimmune hemolytic anemia, a rare diseas…
Jun 12, 2026